Compare Eversource Energy (D/B/A) Common Stock (ES) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Johnson & Johnson — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.67 (market cap $25.11B), while Johnson & Johnson trades at $257.97 (market cap $611.90B). The key difference: Johnson & Johnson is far larger — about 24.4× Eversource Energy (D/B/A) Common Stock's market cap, and Eversource Energy (D/B/A) Common Stock pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.
| ES | JNJ | |
|---|---|---|
Market Cap | $25.11B | $611.90B |
Volume | 3,164,400 | 9,651,904 |
Sector | Utilities | Health |
52-Week High | $76.21 | $278.43 |
52-Week Low | $63.28 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $55.18B | $640.18B |
Dividend Yield | 4.72% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.
Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
